Rapid Medical Diagnostic Kits Market Size to Hit USD 67.0 Billion by 2035 | SNS Insider

The rapid medical diagnostic kits market is projected to grow with North America representing 37% of global market share in 2025. The U.S. is expected to reach USD 16.32B by 2035, while Europe is forecast to reach USD 18.10B, supported by point-of-care expansion, reimbursement initiatives, and home testing adoption.

Analysis

The investable angle is not “more testing” so much as a channel shift: economics migrate from centralized labs toward high-frequency, lower-acuity, consumer-distributed products. That favors scaled platforms with installed distribution and pharmacy relationships, while pressuring pure-play reference labs whose volume growth comes with lower reimbursement per sample and weaker pricing power. If adoption broadens, the hidden winner is the retailer/pharmacy channel, which can monetize traffic and cross-sell, while smaller kit makers risk having their growth competed away into private-label and contract manufacturing.

Near term, the market may over-interpret the headline as a clean demand bull case. The first-order upside is usually seasonal and event-driven, but the more durable catalyst is reimbursement policy: if payors keep shifting coverage toward home and point-of-care formats, the volume uplift can persist for 1-3 quarters. The key reversal risk is that utilization does not expand, it merely substitutes for lab testing, which would leave total industry dollars flatter than the growth narrative implies and compress margins as manufacturers compete on price.

The contrarian view is that this is a quality-of-revenue issue, not a pure growth story. A bigger addressable market can still be bearish for profitability if it fragments into commoditized SKUs and higher channel-sharing with retailers. The thesis would be falsified by weak reimbursement uptake, flat prescription/OTC sell-through at CVS/WBA, or no improvement in testing cadence through the next respiratory season; in that case, diagnostics names should trade like low-growth consumables, not multiple-expansion healthcare growth assets.

Key Decisions for Investors

• Watchlist, not immediate trade: use CVS and WBA as proxies for consumer adoption. Enter only if channel checks show sustained sell-through acceleration over the next 4-6 weeks; upside is traffic/mix leverage, downside is limited because the market already discounts weak core retail pharmacy growth.
• Pair idea for 1-3 months: long ABT / short DGX or LH if reimbursement continues to favor point-of-care and home testing. The long side captures mix shift and distribution leverage; the short side is exposed to volume cannibalization and pricing pressure. Falsify if lab volume growth reaccelerates or hospital send-out pricing improves.
• If you want a higher-beta expression, consider QDEL as a tactical long only after proof of demand in the next earnings cycle. Risk/reward is attractive only if management shows revenue growth above inventory correction, otherwise the stock can stay trapped on margin skepticism.
• Set an alert on CMS/commercial payer policy updates over the next 1-3 months. A favorable reimbursement change is the real catalyst; without it, the thesis becomes a consumer convenience story with limited multiple upside.
• No direct sector long if breadth is weak: if diagnostics ETFs or healthcare equipment names fail to outperform the broader healthcare complex within 2-4 weeks, treat the move as noise and avoid chasing.